Symbols / RANI $1.32 +0.00%
RANI Chart
About
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 161.89M |
| Enterprise Value | 138.05M | Income | -28.32M | Sales | 1.20M |
| Book/sh | -0.16 | Cash/sh | 0.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 105 | IPO | — |
| P/E | — | Forward P/E | -4.17 | PEG | — |
| P/S | 134.91 | P/B | -8.05 | P/C | — |
| EV/EBITDA | -3.45 | EV/Sales | 115.04 | Quick Ratio | 0.22 |
| Current Ratio | 0.26 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.77 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -95.52% |
| ROE | — | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -34.18% | Profit Margin | 0.00% | Shs Outstand | 97.55M |
| Shs Float | 62.15M | Short Float | 12.20% | Short Ratio | 12.83 |
| Short Interest | — | 52W High | 3.87 | 52W Low | 0.39 |
| Beta | 0.41 | Avg Volume | 1.18M | Volume | 610.72K |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $1.32 |
| Price | $1.32 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$1.32
Latest analyst target
3. DCF / Fair value
$-2.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.32
Low
$5.00
High
$11.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-10-20 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-16 | main | Oppenheimer | Outperform → Outperform | $4 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-02-26 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-18 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-16 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-02 | init | Oppenheimer | — → Outperform | $17 |
| 2024-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-06-14 | init | Maxim Group | — → Buy | $15 |
| 2024-06-13 | init | Rodman & Renshaw | — → Buy | $10 |
| 2024-05-09 | main | BTIG | Buy → Buy | $14 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-03-27 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2024-03-25 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-06 | reit | Wedbush | Outperform → Outperform | $8 |
| 2023-11-09 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2023-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
- Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 14 Mar 2026 00
- Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17% - Yahoo Finance Fri, 23 Jan 2026 08
- Rani promotes new CTO to scale drug manufacturing and obesity trial - Stock Titan Wed, 28 Jan 2026 08
- Rani Therapeutics Holdings, Inc. Stock (RANI) Opinions on Billion-Dollar Chugai Deal | RANI Stock News - Quiver Quantitative hu, 23 Oct 2025 07
- Rani Therapeutics stock soars after inking $1 billion potential deal with Chugai - Investing.com Fri, 17 Oct 2025 07
- Can Rani Therapeutics Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- $60.3M Oversubscribed Financing: Rani Therapeutics Prices At-the-Market Placement, Funds Ops Into 2028 - Stock Titan Fri, 17 Oct 2025 07
- $RANI stock is down 13% today. Here's what we see in our data. | RANI Stock News - Quiver Quantitative hu, 30 Oct 2025 07
- Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M - Yahoo Finance UK Mon, 20 Oct 2025 07
- Rani (NASDAQ: RANI) closes at-the-market placement, raises $60.3M; runway into 2028 - Stock Titan hu, 23 Oct 2025 07
- $RANI stock is down 8% today. Here's what we see in our data. - Quiver Quantitative ue, 25 Nov 2025 08
- Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Yahoo Finance hu, 23 Oct 2025 07
- Rani Therapeutics (Nasdaq: RANI) to Join Evercore Healthcare Conference on Dec. 3 - Stock Titan Mon, 24 Nov 2025 08
- Rani (NASDAQ: RANI) expects runway into 2028, announces up to $1.085B Chugai pact - Stock Titan hu, 06 Nov 2025 08
- Insider Sale: 10% owner at $RANI Sells 4,000,000 Shares - Quiver Quantitative Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2083334 | 4354168 | — | Purchase at price 2.09 per share. | IMRAN MIR A | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-23 00:00:00 | D |
| 1 | 5923000 | 15711314 | — | Sale at price 2.41 - 2.77 per share. | SOUTH CONE INVESTMENTS L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-21 00:00:00 | I |
| 2 | 17960 | 29993 | — | Purchase at price 1.67 per share. | MCKINLEY KATE | Officer | — | 2024-12-13 00:00:00 | D |
| 3 | 10296 | 19974 | — | Purchase at price 1.94 per share. | IMRAN TALAT | Chief Executive Officer | — | 2024-12-09 00:00:00 | D |
| 4 | 3829360 | 8118243 | — | Sale at price 2.12 per share. | SOUTH CONE INVESTMENTS L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-15 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -289.17K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.27 |
| NormalizedEBITDA | -46.81M | -61.98M | -61.66M | -51.01M |
| TotalUnusualItems | -3.71M | 0.00 | 0.00 | -1.07M |
| TotalUnusualItemsExcludingGoodwill | -3.71M | 0.00 | 0.00 | -1.07M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.02M | -33.97M | -30.59M | -8.33M |
| ReconciledDepreciation | 1.03M | 822.00K | 548.00K | 497.00K |
| EBITDA | -50.52M | -61.98M | -61.66M | -52.08M |
| EBIT | -51.55M | -62.80M | -62.20M | -52.58M |
| NetInterestIncome | -3.27M | -1.78M | 177.00K | -377.00K |
| InterestExpense | 5.03M | 5.08M | 1.07M | 466.00K |
| InterestIncome | 1.76M | 3.30M | 1.25M | 89.00K |
| NormalizedIncome | -26.30M | -33.97M | -30.59M | -7.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.02M | -33.97M | -30.59M | -8.33M |
| TotalExpenses | 50.63M | 66.10M | 63.45M | 54.32M |
| TotalOperatingIncomeAsReported | -53.31M | -66.10M | -63.45M | -51.60M |
| DilutedAverageShares | 28.48M | 25.50M | 23.82M | 19.53M |
| BasicAverageShares | 28.48M | 25.50M | 23.82M | 19.53M |
| DilutedEPS | -1.05 | -1.33 | -1.28 | -0.43 |
| BasicEPS | -1.05 | -1.33 | -1.28 | -0.43 |
| DilutedNIAvailtoComStockholders | -30.02M | -33.97M | -30.59M | -8.33M |
| NetIncomeCommonStockholders | -30.02M | -33.97M | -30.59M | -8.33M |
| NetIncome | -30.02M | -33.97M | -30.59M | -8.33M |
| MinorityInterests | 26.57M | 33.91M | 32.76M | 44.76M |
| NetIncomeIncludingNoncontrollingInterests | -56.58M | -67.88M | -63.34M | -53.09M |
| NetIncomeContinuousOperations | -56.58M | -67.88M | -63.34M | -53.09M |
| TaxProvision | 0.00 | 70.00K | 41.00K | |
| PretaxIncome | -56.58M | -67.88M | -63.27M | -53.05M |
| OtherIncomeExpense | -3.71M | -1.07M | ||
| SpecialIncomeCharges | -3.71M | 0.00 | 0.00 | -700.00K |
| OtherSpecialCharges | 700.00K | |||
| ImpairmentOfCapitalAssets | 3.71M | 0.00 | ||
| GainOnSaleOfSecurity | -371.00K | |||
| NetNonOperatingInterestIncomeExpense | -3.27M | -1.78M | 177.00K | -377.00K |
| InterestExpenseNonOperating | 5.03M | 5.08M | 1.07M | 466.00K |
| InterestIncomeNonOperating | 1.76M | 3.30M | 1.25M | 89.00K |
| OperatingIncome | -49.60M | -66.10M | -63.45M | -51.60M |
| OperatingExpense | 50.63M | 66.10M | 63.45M | 54.32M |
| ResearchAndDevelopment | 26.68M | 39.62M | 36.61M | 26.48M |
| SellingGeneralAndAdministration | 23.95M | 26.48M | 26.84M | 27.83M |
| GeneralAndAdministrativeExpense | 23.95M | 26.48M | 26.84M | 27.83M |
| OtherGandA | 23.95M | 26.48M | 26.84M | 27.83M |
| TotalRevenue | 1.03M | 0.00 | 0.00 | 2.72M |
| OperatingRevenue | 1.03M | 0.00 | 0.00 | 2.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 33.43M | 26.04M | 25.30M | 19.71M |
| ShareIssued | 33.43M | 26.04M | 25.30M | 19.71M |
| NetDebt | 20.85M | 23.52M | 2.14M | |
| TotalDebt | 29.71M | 30.10M | 30.21M | 0.00 |
| TangibleBookValue | 1.99M | 12.87M | 36.85M | 47.41M |
| InvestedCapital | 26.61M | 42.25M | 66.00M | 47.41M |
| WorkingCapital | 9.85M | 42.86M | 96.11M | 116.95M |
| NetTangibleAssets | 1.99M | 12.87M | 36.85M | 47.41M |
| CapitalLeaseObligations | 5.10M | 718.00K | 1.06M | 0.00 |
| CommonStockEquity | 1.99M | 12.87M | 36.85M | 47.41M |
| TotalCapitalization | 11.61M | 37.35M | 66.00M | 47.41M |
| TotalEquityGrossMinorityInterest | 3.49M | 25.44M | 74.00M | 121.57M |
| MinorityInterest | 1.50M | 12.58M | 37.15M | 74.16M |
| StockholdersEquity | 1.99M | 12.87M | 36.85M | 47.41M |
| GainsLossesNotAffectingRetainedEarnings | 5.00K | -12.00K | -73.00K | 0.00 |
| RetainedEarnings | -102.91M | -72.89M | -38.92M | -8.33M |
| AdditionalPaidInCapital | 104.89M | 85.76M | 75.84M | 55.74M |
| CapitalStock | 5.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 5.00K | 5.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 33.14M | 32.47M | 34.02M | 2.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 13.25M | 24.48M | 29.21M | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 13.25M | 24.48M | 29.21M | 0.00 |
| LongTermCapitalLeaseObligation | 3.64M | 0.00 | 59.00K | 0.00 |
| LongTermDebt | 9.61M | 24.48M | 29.15M | |
| CurrentLiabilities | 19.89M | 7.99M | 4.82M | 2.64M |
| OtherCurrentLiabilities | 283.00K | 254.00K | 538.00K | 398.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 16.46M | 5.62M | 1.01M | |
| CurrentCapitalLeaseObligation | 1.46M | 718.00K | 1.01M | 0.00 |
| CurrentDebt | 15.00M | 4.90M | ||
| OtherCurrentBorrowings | 15.00M | 4.90M | ||
| PayablesAndAccruedExpenses | 3.15M | 2.12M | 3.27M | 2.24M |
| CurrentAccruedExpenses | 1.79M | 1.47M | 1.76M | 1.04M |
| InterestPayable | 931.00K | 500.00K | 69.00K | |
| Payables | 1.36M | 648.00K | 1.51M | 1.21M |
| DuetoRelatedPartiesCurrent | 52.00K | 53.00K | 126.00K | |
| AccountsPayable | 1.36M | 648.00K | 1.46M | 1.08M |
| TotalAssets | 36.63M | 57.92M | 108.03M | 124.21M |
| TotalNonCurrentAssets | 6.89M | 7.07M | 7.10M | 4.61M |
| OtherNonCurrentAssets | 246.00K | 246.00K | ||
| NetPPE | 6.64M | 6.82M | 7.10M | 4.61M |
| AccumulatedDepreciation | -4.64M | -3.67M | -2.85M | -2.33M |
| GrossPPE | 11.28M | 10.49M | 9.95M | 6.94M |
| Leases | 1.66M | 1.59M | 1.55M | 1.23M |
| ConstructionInProgress | 31.00K | 3.90M | 4.42M | 3.87M |
| OtherProperties | 9.33M | 4.74M | 3.73M | 1.73M |
| MachineryFurnitureEquipment | 269.00K | 261.00K | 261.00K | 102.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 29.74M | 50.85M | 100.92M | 119.59M |
| OtherCurrentAssets | 1.68M | 2.31M | 2.44M | 2.14M |
| RestrictedCash | 500.00K | 0.00 | ||
| PrepaidAssets | 2.14M | |||
| Receivables | 428.00K | 0.00 | 0.00 | |
| OtherReceivables | 428.00K | |||
| NotesReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 27.64M | 48.54M | 98.48M | 117.45M |
| OtherShortTermInvestments | 23.88M | 42.67M | 71.47M | 0.00 |
| CashAndCashEquivalents | 3.76M | 5.86M | 27.01M | 117.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -35.76M | -52.47M | -48.13M | -32.75M |
| RepaymentOfDebt | -5.00M | 0.00 | 0.00 | -4.57M |
| IssuanceOfDebt | 0.00 | 29.57M | 1.72M | |
| IssuanceOfCapitalStock | 18.26M | 0.00 | 0.00 | 79.97M |
| CapitalExpenditure | -268.00K | -1.23M | -1.62M | -506.00K |
| InterestPaidSupplementalData | 4.11M | 4.18M | 730.00K | 285.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 35.00K | 48.00K | 73.00K |
| EndCashPosition | 4.26M | 6.36M | 27.51M | 117.45M |
| BeginningCashPosition | 6.36M | 27.51M | 117.45M | 73.06M |
| ChangesInCash | -2.10M | -21.14M | -89.95M | 44.40M |
| FinancingCashFlow | 13.59M | 233.00K | 29.00M | 77.15M |
| CashFlowFromContinuingFinancingActivities | 13.59M | 233.00K | 29.00M | 77.15M |
| NetOtherFinancingCharges | -47.00K | -162.00K | -886.00K | |
| ProceedsFromStockOptionExercised | 370.00K | 395.00K | 317.00K | 26.00K |
| NetPreferredStockIssuance | 0.00 | 6.32M | ||
| PreferredStockIssuance | 0.00 | 6.32M | ||
| NetCommonStockIssuance | 18.26M | 0.00 | 0.00 | 73.65M |
| CommonStockIssuance | 18.26M | 0.00 | 0.00 | 73.65M |
| NetIssuancePaymentsOfDebt | -5.00M | 0.00 | 29.57M | -2.85M |
| NetLongTermDebtIssuance | -5.00M | 0.00 | 29.57M | -2.85M |
| LongTermDebtPayments | -5.00M | 0.00 | 0.00 | -4.57M |
| LongTermDebtIssuance | 0.00 | 29.57M | 1.72M | |
| InvestingCashFlow | 19.81M | 29.86M | -72.44M | -506.00K |
| CashFlowFromContinuingInvestingActivities | 19.81M | 29.86M | -72.44M | -506.00K |
| NetInvestmentPurchaseAndSale | 20.08M | 31.09M | -70.82M | 0.00 |
| SaleOfInvestment | 77.55M | 104.35M | 3.00M | 0.00 |
| PurchaseOfInvestment | -57.47M | -73.26M | -73.82M | 0.00 |
| NetPPEPurchaseAndSale | -268.00K | -1.23M | -1.62M | -506.00K |
| PurchaseOfPPE | -268.00K | -1.23M | -1.62M | -506.00K |
| OperatingCashFlow | -35.50M | -51.24M | -46.52M | -32.24M |
| CashFlowFromContinuingOperatingActivities | -35.50M | -51.24M | -46.52M | -32.24M |
| ChangeInWorkingCapital | -544.00K | -2.14M | 509.00K | -3.43M |
| ChangeInOtherWorkingCapital | -2.72M | |||
| ChangeInOtherCurrentLiabilities | -1.81M | -1.04M | -764.00K | 0.00 |
| ChangeInOtherCurrentAssets | 0.00 | -245.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 1.06M | -1.14M | 768.00K | 1.26M |
| ChangeInAccruedExpense | 350.00K | -540.00K | 605.00K | 739.00K |
| ChangeInPayable | 711.00K | -595.00K | 163.00K | 524.00K |
| ChangeInAccountPayable | 711.00K | -595.00K | 163.00K | 543.00K |
| ChangeInPrepaidAssets | 631.00K | 282.00K | 505.00K | -1.98M |
| ChangeInReceivables | -428.00K | 0.00 | ||
| OtherNonCashItems | 2.04M | 1.27M | 841.00K | 109.00K |
| StockBasedCompensation | 16.03M | 19.01M | 15.78M | 22.59M |
| AssetImpairmentCharge | 3.71M | 0.00 | ||
| AmortizationOfSecurities | -1.25M | -2.32M | -851.00K | 0.00 |
| DepreciationAmortizationDepletion | 1.03M | 822.00K | 548.00K | 497.00K |
| DepreciationAndAmortization | 1.03M | 822.00K | 548.00K | 497.00K |
| Depreciation | 800.00K | 500.00K | ||
| OperatingGainsLosses | 65.00K | 1.07M | ||
| GainLossOnInvestmentSecurities | 371.00K | |||
| GainLossOnSaleOfPPE | 65.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -56.58M | -67.88M | -63.34M | -53.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RANI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|